EGFR and non-small cell lung carcinoma: These findings could explain the conflicting results of clinical trials using autophagy inhibitors, and indicate that strategies to correct ATG16‐L1 splicing and/or increase autophagy in combination with EGFR‐TKI may represent new therapeutic approaches to overcome resistance in selected NSCLC patients.